Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

By sjmartinez • April 18, 2023

Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA, Currier JS, Eron JJ, Javan AC, Bender Ignacio R, Margolis D, Zhu Q, Ma J, Zhong L, Yan L, D'Andrea Nores U, Hoover K, Mocherla B, Choudhary MC, Deo R, Ritz J, Fischer WA, Fletcher CV, Li JZ, Hughes MD, Smith D, Daar ES; ACTIV-2/A5401 Study Team. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. Ann Intern Med. 2023 Apr 18. doi: 10.7326/M22-3428. Epub ahead of print. PMID: 37068272.

Tags: Infectious Diseases, Publications

Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With HIV

Grinspoon SK, Watanabe M, Ribaudo HJ, Bloomfield GS, Fichtenbaum CJ, Umbleja T, Chu SM, Fitch KV, Diggs MR, Zhao S, Looby SE, Currier JS, Aberg[...]

Adjunctive GM-CSF therapy enhances host defense against systemic Candida auris infection in immunosuppressed mice

Mattos EC, Das Gupta K, Quintanilla D, Hautau H, Ibrahim AS, Singh S. Adjunctive GM-CSF therapy enhances host defense against systemic Candida auris infection in immunosuppressed mice.[...]

The path ahead: Building community between palliative care and infectious disease teams

Karlin D, Vijayan T. The path ahead: Building community between palliative care and infectious disease teams. Clin Microbiol Infect. 2026 Feb 2:S1198-743X(26)00034-0. doi: 10.1016/j.cmi.2026.01.029. Epub[...]